What is ASND's five-year median EV/Sales?

There are not enough weekly readings yet for a five-year median EV/Sales.

Does a low historical rank mean a stock is a buy?

No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Ascendis Pharma A/S (ASND) valuation history

Health Care

$253.00

Latest weekly close · Market cap $16.6B

Ascendis Pharma's EV/Sales is unavailable because recent financial data is missing (as of Oct 30, 2026).

Forward P/E 25.3× (analyst estimates, not ranked).
No P/S: recent financial data is missing.
No EV/EBITDA: recent financial data is missing.

No EV/Sales chart for ASND right now

ASND has no weekly EV/Sales history to chart yet.

EV/Sales

n/mnot ranked

EV/Sales needs more weekly history to be ranked.

Growth, last 12 months vs the year before

Revenue: +115%
EPS: n/m

Health Care peers on EV/Sales

Each percentile compares a stock with its own last five years.

Compare ASND with peers

Health Care peers of ASND on EV/Sales
Stock	EV/Sales	Versus its own history	5-year percentile
ABBVAbbVie	8.9×	Historically high	100
AMGNAmgen	7.7×	Historically high	98
ARWRArrowhead Pharmaceuticals Inc	11.6×	Within its usual range	32
BIIBBiogen	4.2×	Historically high	91
BMRNBioMarin Pharmaceutical Inc	4.3×	Below its usual range	29

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on ASND

No articles about ASND yet. How valuation percentiles work

Loading peers and related research…

About this history

What is ASND's current EV/Sales?: Ascendis Pharma's EV/Sales is unavailable because recent financial data is missing (as of Oct 30, 2026).
What is ASND's five-year median EV/Sales?: There are not enough weekly readings yet for a five-year median EV/Sales.
Does a low historical rank mean a stock is a buy?: No. The rank compares ASND only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.